Email this article The base to choose low molecular weight heparins in cancer patients
- Authors: Roitman E.V.1, Andrianova M.Y.2, Vardanyan A.V3, Roumiantsev S.A4
-
Affiliations:
- N.I. Pirogov Russian National Research Medical University
- B.V. Petrovsky National Research Center of Surgery
- Russian Medical Academy of Postgraduate Education
- Centre of Pediatric Hematology Oncology Immunology named after D. Rogachev
- Issue: Vol 20, No 6 (2015)
- Pages: 50-53
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40233
- DOI: https://doi.org/10.17816/onco40233
- ID: 40233
Cite item
Full Text
Abstract
The review discusses coagulation peculiarities due to cancer that are the pathophysiological basis for choice among low-molecular-weight heparins represented in Russia today.
Full Text
##article.viewOnOriginalSite##About the authors
Eugene V. Roitman
N.I. Pirogov Russian National Research Medical University
Email: roitman@hemostas.ru
д-р биол. наук, проф. каф. онкологии, гематологии и лучевой терапии педиатрического факультета 117997, Moscow, Russian Federation
M. Yu Andrianova
B.V. Petrovsky National Research Center of Surgery119991, Moscow, Russian Federation
A. V Vardanyan
Russian Medical Academy of Postgraduate Education125284, Moscow, Russian Federation
S. A Roumiantsev
Centre of Pediatric Hematology Oncology Immunology named after D. Rogachev117997, Moscow, Russian Federation
References
- Морозов К.М., Андрианова М.Ю., Ройтман Е.В., Румянцев С.А. Биоэквивалентность антитромботических препаратов Эниксум® и Клексан®. Тромбоз, гемостаз и реология. 2014; 2: 69-73.
- Mousa S.A. Role of current and emerging antithrombotics in thrombosis and cancer. Drugs Today (Barc.). 2006; 42 (5): 331-50.
- Птушкин В.В. Рекомендации по профилактике и лечению тромбозов вен и тромбоэмболий у больных с онкологическими заболеваниями. Онкогематология. 2009; 2: 75-8.
- Птушкин В.В. Профилактика тромботических осложнений в онкологии. Тромбоз, гемостаз и реология. 2013; 1: 29-37.
- Макацария А.Д., Воробьев А.В., Бицадзе В.О. Злокачественные новообразования, тромбофилия, тромбозы: монография. М.: Триада-Х; 2008.
- Воробьев А.В., Макацария А.Д. Противотромботическая терапия у онкологических больных. Практическая медицина. 2014; 8(5): 18-28.
- Falanga A. Tumor cell prothrombotic properties. Haemostasis. 2001; 31 (Suppl. 1): 1-4.
- Falanga A., Marchetti M., Vignoli A., Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin. Adv. Hematol. Oncol. 2003; 1 (11): 673-8.
- Falanga A. Thrombophilia in cancer. Semin. Thromb. Hemost. 2005; 31 (1): 104-10.
- Xie W.Z., Leibl M., Clark M.R., Dohrmann P., Kunze T., Gieseler F. Activation of the coagulation system in cancerogenesis and metastasation. Biomed. Pharmacother. 2005; 59 (3): 70-5.
- Тen C.H., Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol. Haemost. Thromb. 2008; 36 (3-4): 122-30.
- Samama M.M., Gerotziafas G. Comparative pharmacokinetics of LMWHs. Semin. Thromb. Hemost. 2000; 26 (Suppl. 1): 31-8.
- Mousa S.A. Antithrombotics in thrombosis and cancer. Expert Rev. Cardiovasc. Ther. 2003; 1 (2): 283-91.
- Mousa S.A. Low-molecular-weight heparins in thrombosis and cancer: emerging links. Cardiovasc. Drug Rev. 2004; 22 (2): 121-34.
- van Dongen C.J., MacGillavry M.R., Prins M.H. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst. Rev. 2005; 3: Art. CD003074.
- Prandoni P., Lensing A.W., Piccioli A., Bernardi E., Simioni P., Girolami B. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100 (10): 3484-8.
- Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 2003; 349: 146-53.
- Nishioka J., Goodin S. Low-molecular-weight heparin in cancerassociated thrombosis: treatment, secondary prevention, and survival. J. Oncol. Pharm. Pract. 2007; 13 (2): 85-97.
- Российские клинические рекомендации по профилактике и лечению венозных тромбоэмболических осложнений у онкологических больных. М.: Планида; 2012.
- Ройтман Е.В., Андрианова М.Ю., Колесникова И.М., Спиридонова Е.А., Румянцев С.А. Фармакопрофилактика венозного тромбоэмболизма сегодня. Нужен ли лабораторный контроль? Клиническая патофизиология. 2013; 4: 28-33.
- Ройтман Е.В. Know-how лабораторной диагностики состояния системы свертывания крови. Российский журнал детской гематологии и онкологии. 2015; 1: 27-35.
